Sarepta Therapeutics (SRPT) Falls as Anthem says Exondys 51 Not Medically Necessary

October 7, 2016 10:39 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Sarepta Therapeutics (NASDAQ: SRPT) ticks lower after Anthem says Exondys 51 not medically necessary. Shares are down 3.2%.

Anthem's position statement:

"The use of eteplirsen is considered investigational and not medically necessary for all indications, including but not limited to the treatment of Duchenne muscular dystrophy."


Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Momentum Movers, Trader Talk

Add Your Comment